These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16568897)

  • 1. Virus fitness: concept, quantification, and application to HIV population dynamics.
    Quiñones-Mateu ME; Arts EJ
    Curr Top Microbiol Immunol; 2006; 299():83-140. PubMed ID: 16568897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures for reliable estimation of viral fitness from time-series data.
    Bonhoeffer S; Barbour AD; De Boer RJ
    Proc Biol Sci; 2002 Sep; 269(1503):1887-93. PubMed ID: 12350250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.
    Berkhout B
    J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflicting Selection Pressures Will Constrain Viral Escape from Interfering Particles: Principles for Designing Resistance-Proof Antivirals.
    Rast LI; Rouzine IM; Rozhnova G; Bishop L; Weinberger AD; Weinberger LS
    PLoS Comput Biol; 2016 May; 12(5):e1004799. PubMed ID: 27152856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fitness variations and their impact on the evolution of antiretroviral drug resistance.
    Menéndez-Arias L; Martínez MA; Quiñones-Mateu ME; Martinez-Picado J
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):355-71. PubMed ID: 14754435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for positive epistasis in HIV-1.
    Bonhoeffer S; Chappey C; Parkin NT; Whitcomb JM; Petropoulos CJ
    Science; 2004 Nov; 306(5701):1547-50. PubMed ID: 15567861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
    Cong ME; Youngpairoj AS; Aung W; Sharma S; Mitchell J; Dobard C; Heneine W; Garcia-Lerma JG
    Virology; 2011 Apr; 412(2):435-40. PubMed ID: 21334708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
    Clementi M; Canducci F; Bagnarelli P; Menzo S
    New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV evolution and escape.
    Richman DD; Little SJ; Smith DM; Wrin T; Petropoulos C; Wong JK
    Trans Am Clin Climatol Assoc; 2004; 115():289-303. PubMed ID: 17060974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.
    Kijak GH; Simon V; Balfe P; Vanderhoeven J; Pampuro SE; Zala C; Ochoa C; Cahn P; Markowitz M; Salomon H
    J Virol; 2002 Jul; 76(14):7000-9. PubMed ID: 12072500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of drug resistance mutations in HIV from constraints on natural evolution.
    Butler TC; Barton JP; Kardar M; Chakraborty AK
    Phys Rev E; 2016 Feb; 93(2):022412. PubMed ID: 26986367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.
    Ariën KK; Venkatraj M; Michiels J; Joossens J; Vereecken K; Van der Veken P; Heeres J; De Winter H; Heyndrickx L; Augustyns K; Vanham G
    J Antimicrob Chemother; 2016 May; 71(5):1159-68. PubMed ID: 26850721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
    Maldonado JO; Mansky LM
    Viruses; 2018 Jul; 10(7):. PubMed ID: 30029500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
    Collins JA; Thompson MG; Paintsil E; Ricketts M; Gedzior J; Alexander L
    J Virol; 2004 Jan; 78(2):603-11. PubMed ID: 14694092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.
    Hernandez MM; Fahrny A; Jayaprakash A; Gers-Huber G; Dillon-White M; Audigé A; Mulder LCF; Sachidanandam R; Speck RF; Simon V
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31801862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus population dynamics, fitness variations and the control of viral disease: an update.
    Domingo E; Mas A; Yuste E; Pariente N; Sierra S; Gutiérrez-Riva M; Menéndez-Arias L
    Prog Drug Res; 2001; 57():77-115. PubMed ID: 11728003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.
    Smith RJ; Okano JT; Kahn JS; Bodine EN; Blower S
    Science; 2010 Feb; 327(5966):697-701. PubMed ID: 20075214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies.
    Eberle J; Gürtler L
    Intervirology; 2012; 55(2):79-83. PubMed ID: 22286874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.